Case Report: Multimodal treatment of pediatric H3G34-mutant diffuse hemispheric glioma: a safety and feasibility case report combining precision medicine and tumor treating fields with conventional care
Abstract
Diffuse hemispheric glioma, H3G34-mutant (H3G34-DHG) is a rare, highly malignant brain tumour with a dismal prognosis and a median time to progression (TTP) of 10 months with best available practice. We report a case of a 13-year-old boy with H3G34-DHG who underwent a multimodal treatment strategy, combining backbone chemotherapy, radiotherapy, surgery, tumour treating fields with Wilms Tumour-1 (WT1) directed dendritic cell immunotherapy and targeted therapy (STAT3-inhibition). The patient had a TTP of 787 days or 25 months, more than double the literature-reported median, with preserved quality of life and showing downregulation of WT1. This case supports the feasibility of combining multiple therapeutic modalities in the management of high-risk paediatric brain tumours, with potential synergy between different treatment elements. While access to novel therapies in the context of clinical trials remains essential, this case illustrates how treatment can be tailored to individual tumour biology and tolerability. The rationale presented in this detailed case report can inform future trial designs and promote precision medicine approaches for this tumour type.
Related
- Severe Pediatric Ocular Surface Disease: Multimodal Approach and Treatment
- Prospective Case Series to Determine the Feasibility, Diagnostic Yield and Safety of Performing EBUS Guided Trans‐Bronchial Mediastinal Cryobiopsy (EBUS‐TBMC) of Lymph Nodes Using 1.1 mm Cryoprobe Through a Working Channel of Linear EBUS Bronchoscope Versus Conventional En‐Bloc Cryobiopsy
- A prospective cross-sectional diagnostic feasibility study: musculoskeletal ultrasound for pediatric bone age evaluation
- Contemporary and Emerging Therapeutic Strategies in Hypoparathyroidism: From Conventional Treatment to Restoration of Parathyroid Function
- WHAT IS NORMAL? MULTIMODAL CHARACTERIZATION OF NON-DISEASED PEDIATRIC DUODENAL BIOPSIES USING MACHINE LEARNING IMAGE ANALYSIS AND TRANSCRIPTOMICS
BibTeX
@article{genechten2026case,
title = {{Case Report: Multimodal treatment of pediatric H3G34-mutant diffuse hemispheric glioma: a safety and feasibility case report combining precision medicine and tumor treating fields with conventional care}},
author = {Toon Van Genechten and Alexander Claviez and Sebastian Oberbeck and Wouter P. Nieuwenhuis and Nelleke Tolboom and Mariska Sie and Oscar H.J. Eelkman Rooda and Mariette E.G. Kranendonk and Esther Hulleman and Maxime De Laere and Jaques Van Heerden and Zwi Berneman and Eva Lion and Niels E. Franke},
journal = {Frontiers in Oncology},
year = {2026},
month = nov,
doi = {10.3389/fonc.2026.1953452},
url = {https://www.frontiersin.org/articles/10.3389/fonc.2026.1953452},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Case Report: Multimodal treatment of pediatric H3G34-mutant diffuse hemispheric glioma: a safety and feasibility case report combining precision medicine and tumor treating fields with conventional care
AU - Toon Van Genechten
AU - Alexander Claviez
AU - Sebastian Oberbeck
AU - Wouter P. Nieuwenhuis
AU - Nelleke Tolboom
AU - Mariska Sie
AU - Oscar H.J. Eelkman Rooda
AU - Mariette E.G. Kranendonk
AU - Esther Hulleman
AU - Maxime De Laere
AU - Jaques Van Heerden
AU - Zwi Berneman
AU - Eva Lion
AU - Niels E. Franke
PY - 2026
DA - 2026/11/02
JO - Frontiers in Oncology
DO - 10.3389/fonc.2026.1953452
UR - https://www.frontiersin.org/articles/10.3389/fonc.2026.1953452
AB - Diffuse hemispheric glioma, H3G34-mutant (H3G34-DHG) is a rare, highly malignant brain tumour with a dismal prognosis and a median time to progression (TTP) of 10 months with best available practice. We report a case of a 13-year-old boy with H3G34-DHG who underwent a multimodal treatment strategy, combining backbone chemotherapy, radiotherapy, surgery, tumour treating fields with Wilms Tumour-1 (WT1) directed dendritic cell immunotherapy and targeted therapy (STAT3-inhibition). The patient had a TTP of 787 days or 25 months, more than double the literature-reported median, with preserved quality of life and showing downregulation of WT1. This case supports the feasibility of combining multiple therapeutic modalities in the management of high-risk paediatric brain tumours, with potential synergy between different treatment elements. While access to novel therapies in the context of clinical trials remains essential, this case illustrates how treatment can be tailored to individual tumour biology and tolerability. The rationale presented in this detailed case report can inform future trial designs and promote precision medicine approaches for this tumour type.
SN - 2234-943X
ER -